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ABSTRACT OF THESIS 
 
 
 
 
IDENTIFICATION AND CHARACTERIZATION OF CONTACT SITES BETWEEN 
HUMAN CHORIONIC GONADOTROPIN AND THE AMINO TERMINAL REGION 
OF THE LUTEINIZING HORMONE/CHORIOGONADOTROPIN RECEPTOR 
 
 
 The luteinizing hormone / choriogonadotropin receptor (LH/CG-R) is a member of the 
G protein-coupled receptor family.  The LH/CG-R has seven transmembrane helices, three 
exoloops, three cytoloops, a C-terminal tail, and an extensive N-terminal exodomain.  The 
exodomain is capable of binding hormone with high affinity without hormone action.  Previous 
studies have shown that the amino-terminal region of the LH/CG receptor contacts both subunits 
of human chorionic gonadotropin (hCG).  In particular, three residues (Leu20, Cys22, and Gly24) 
were found to be crucial for hormone binding.  In this thesis work, benzoylphenylalanine (Bpa), 
a photoactivatable reagent, was used to continue investigating the interactions of the N-terminal 
region of the LH/CG-R with hCG.  Bpa has been directly incorporated at a defined position into 
peptides representing amino acids 17-36 of the LH/CG-R.  These peptides were radiolabeled 
with 125I and used in photoaffinity labeling studies to identify and characterize the contact site(s) 
between the N-terminal region of the LH/CG-R and hCG.  Results suggest that Cys22 is the 
primary contact residue in this region.  Peptide and hormone concentration dependent as well as 
UV duration dependent photoaffinity labeling experiments confirm that the photolabeling of 
hCG by hLHR17-36(C22Bpa) is specific.  Competition of labeling studies indicate that the hLHR17-
36(C22Bpa) peptide is a good mimic of the wild type N-terminal portion of the receptor.  In-gel 
digestions of photolabeled hCG α and photolabeled hCG β with CNBr indicate that the N-
terminal regions of both hCG α and hCG β were photoaffinity labeled by hLHR17-36(C22Bpa).  
Based on the fact that the N-terminal regions of each subunit are located on the convex side of 
the heterodimer, these results provide evidence that the N-terminal portion of the receptor wraps 
around the back of hCG, contacting the convex face of the hormone.   
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CHAPTER ONE:  INTRODUCTION AND BACKGROUND 
 
A.  Glycoprotein Hormones 
 
1.  Biological Function 
 
 Chorionic gonadotropin (CG), luteinizing hormone (LH), follicle stimulating hormone 
(FSH), and thyroid stimulating hormone (TSH) are members of the glycoprotein hormone 
family.  LH, FSH, and TSH are secreted by the anterior pituitary gland.  LH and FSH stimulate 
ovarian and testicular functions by regulating gametogenesis and steroid hormone synthesis in 
the gonads.  TSH regulates the release of thyroid hormones.  In contrast to LH, FSH, and TSH, 
CG is of placental origin [1].  CG acts like pituitary LH to maintain progesterone and estrogen 
secretion by the ovarian corpus luteum through the first trimester of pregnancy [2]. 
 FSH plays a crucial role in the production of the female gamete.  FSH selects the 
dominant follicle, the follicle destined for ovulation, and stimulates follicular development.  It 
also promotes antrum formation and induces the expression of LH receptors on the surface of 
granulosa cells, preparing these cells for the midcycle LH surge.  The absence of FSH in the 
female results in infertility [3].   
FSH has been believed to be essential for the initiation of spermatogenesis.  However, 
mice lacking the FSH β subunit gene remain fertile.  In contrast to their wild-type littermates, the 
testes of these mice are small and produce less sperm, most likely reflecting the effect of FSH on 
Sertoli cell number and function.  The possibility does exist that FSH plays a more important 
role in male primate fertility [3]. 
LH initiates steroidogenesis in the thecal cells of the follicle and the Leydig cells of the 
testis.  This glycoprotein hormone also promotes the ovulation and luteinization of fully 
developed follicles.  LH and FSH have synergistic effects on estradiol synthesis in the ovary, due 
to the fact that FSH promotes the production of estradiol from androgens.  LH may also help 
maintain corpus luteum progesterone production, although this role appears to vary greatly 
among species.  In males, LH triggers the synthesis of androgens needed for spermatogenesis 
and the development of secondary sexual characteristics [3].   
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CG is closely related in structure and activity to LH.  CG maintains pregnancy in 
primates, horses, donkeys, and zebras but few other animals.  Secretion of hCG, human 
chorionic gonadotropin, begins at about the time of implantation and reaches peak levels during 
the first trimester [3].  hCG serves as a signal to the ovary to maintain the corpus luteum thus 
prolonging luteal progesterone synthesis.  hCG binds to LH/CG receptors expressed on the 
surface of luteal cells and granulosa cells, resulting in the activation of adenylyl cyclase and 
production of intracellular cAMP.  Other intracellular messengers could also be activated by 
hCG [4].  In the absence of hCG, the decline in maternal LH due to inhibition of the pituitary by 
progesterone would result in menstruation and spontaneous abortion of the embryo [2]. 
LH/CG receptors have also been found in the endometrium, myometrium, and the 
placenta.  This suggests that hCG could be playing a broader role throughout pregnancy than 
previously assumed.  hCG actions within the placenta direct the differentiation of 
cytotrophoblastic cells into the syncytiotophoblast.  In the developing fetus, hCG is thought to 
regulate testosterone production in the testes, which in turn propels internal and external genitalia 
differentiation [4]. 
In comparison with other animals, relatively high quantities of the gonadotropins (LH, 
CG, and FSH) are excreted in the urine of humans [3].  In fact, hCG detection in urine or serum 
serves as the basis of the pregnancy test.  Elevated levels of maternal serum and urine hCG are 
also used in the prediction of adverse pregnancy outcomes and in screening for fetal Down 
syndrome.  Interestingly, more than one-fourth of ovarian tumors secrete hCG.  Among testicular 
tumors, about 66% of nonseminomatous germ cell tumors and 5% of seminomas secrete the β 
subunit of hCG [4].  Fragments of the β subunit of hCG have also been detected in urine and 
serum.  Expression of the β core fragment, a version of the hCG β subunit which lacks N-
terminal residues 1-5, C-terminal residues 93-145, and loop 2 (residues 41-54), has been linked 
to cervical carcinoma and could therefore potentially be used as a tumor marker [3].   
 
2.  Structure 
 
Each of the glycoprotein hormones is comprised of two subunits:  a common alpha 
subunit, and a hormone-specific beta subunit.  The alpha subunit consists of 92 amino acids and 
the length of the beta subunit varies from hormone to hormone.  The glycoprotein beta subunits 
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all share considerable structural homology, and are thought to have evolved from a common 
precursor. Interestingly, the hCG beta subunit has a carboxy-terminal extension which other 
members of the group lack.  When compared with hLH beta, the hCG beta subunit has 24 
additional residues resulting in a complete beta subunit length of 145 amino acids.  The carboxyl 
terminal segment of hCG beta is rich in proline and serine residues [1].  Four of the latter have 
O-linked carbohydrate chains [5].   
 The alpha and beta subunits associate non-covalently to form the hormone dimer.  
Specific interactions between the two subunits are crucial for hormonal activity, with receptor 
specificity dictated by the hormone beta subunit.  When hybrid hormones are prepared, for 
example the beta subunit of bovine TSH plus the alpha subunit of bovine LH, the beta subunit 
used always determines hormonal specificity.  Additional studies have shown that hybrid LH 
preparations bind largely but not solely to receptors based on the identity of the hormone beta 
subunit [1].     
 The common alpha subunit of human glycoprotein hormones includes ten cysteine 
residues which form five intrasubunit disulphide linkages.  The glycoprotein beta subunits, while 
varying in size, contain twelve cysteines which form six disulphide bonds.  The crystal structure 
of hCG shows that the alpha and beta subunits share a similar topology, with three of the 
disulphide bonds forming an unusual knot (Figure 1-1).  This cysteine-knot motif forms the 
framework of each subunit, and is found in some growth factors [6]. 
 One region of the hCG beta subunit plays an extraordinary part in the association of alpha 
and beta to form the heterodimer.  In heterodimeric hCG, the loop from Cys90 to Cys110 in the 
beta subunit wraps around the alpha subunit like a seatbelt.  The beta disulphide linkage Cys26- 
Cys110 is completed after the association of alpha and beta, indicating that the seatbelt plays an 
important role in maintaining the structural integrity of the heterodimer.  This seatbelt 
arrangement is thought to exist in all of the glycoprotein hormones [6].  The recent 
crystallization of FSH confirms that this hormone also has a seatbelt loop [7]. 
 Approximately 34% of the weight of native hCG can be attributed to complex 
carbohydrates [6].  hCG has four N-linked carbohydrates, two in the alpha subunit at Asn52 and 
Asn78 and two in the beta subunit at Asn13 and Asn30 [8].  Four additional O-linked carbohydrate 
moieties at Ser121, 127, 132,138 make hCG the most heavily glycosylated member of the glycoprotein 
hormone family [5] [6].    
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Glycosylation is not necessary for receptor binding.  When the bulk of the carbohydrates 
are removed from hCG by treatment with anhydrous hydrofluoric acid, the resulting 
deglycosylated hormone binds receptors with slightly increased affinity but with a loss of 
hormone action [9] [10] [11].  Specifically, the N-linked carbohydrates have been shown to be 
involved in signal transduction.  Site-directed mutagenesis studies indicate that carbohydrates in 
the alpha subunit, particularly the carbohydrate chain at Asn52, play a critical role in hCG signal 
transduction [12,13].  Additional studies have shown that glycans impact the rate of clearance of 
the hormone from the body [1].   
 
B.  The Luteinizing Hormone/Choriogonadotropin (LH/CG) Receptor 
 
1.  Expression and Structure 
 
 LH and CG interact with the LH/CG receptor to bring about hormonal actions.  The 
majority of LH/CG receptors are located in the gonads.  Receptor expression has been reported 
in other tissues including the rat prostate gland, and in the human non-pregnant uterus, placenta, 
fallopian tubes, umbilical cord, uterine vessels, lymphocytes, and brain [3] [14].  LH/CG 
receptors have also been detected in epithelial cells of the normal mammary gland, in benign 
breast lesions, malignant breast tumors, and in several cancer cell lines [14]. 
 The LH/CG receptor is a member of the superfamily of G protein-coupled receptors 
(GPCRs).  Approximately 2000 GPCRs have been cloned.  All GPCRs have an extracellular N-
terminal segment, seven transmembrane domains, three exoloops, three cytoloops, and a C-
terminal segment.  N-terminal segments, exoloops, cytoloops, and C-terminal segments vary 
greatly in size, indicative of the diverse functions of GPCR family members.  Interestingly, the 
N-terminal portion of the LH/CG receptor is structurally equivalent to the entire molecule of 
many other GPCRs [15]. 
The LH/CG receptor cDNA encodes a 674 amino acid glycoprotein (Figure 1-2) [16] 
[17].  An N-terminal cleavable signal sequence, 22 amino acids in humans, directs insertion of 
the receptor into the endoplasmic reticulum processing pathway [14].  The molecular weight of 
the receptor is calculated to be 75 kDa.  Glycosylation of the LH/CG receptor results in a 
molecular weight of 85 to 92 kDa.  The sequence of the LH/CG receptor indicates that it is 
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comprised of two approximately equal halves:  the extracellular amino terminal half, and the 
membrane-associated carboxyl terminal half  [18].   
The extracellular amino terminal portion of the receptor, also known as the exodomain, 
consists of 341 amino acids and is responsible for binding hormone with high affinity [19] [20] 
[21].  The exodomain contains eight to nine copies of a motif known as the leucine-rich repeat 
(LRR) [16].  An LRR is approximately 25 amino acids long and is comprised of an α helix, a 
turn, a β sheet, and another turn.  LRRs are typically stacked in parallel with helices next to 
helices and sheets next to sheets forming a horseshoe-shaped structure (Figure 1-3).  The LRR 
motif was first identified in ribonuclease inhibitor [22].     
The LH/CG receptor exodomain has six consensus N-linked glycosylation sites [18].  
Enzymatic deglycosylation of the receptor does not hinder hormone binding, suggesting that the 
removed carbohydrates are not necessary for hormone binding [23].  There is no evidence for O-
linked glycosylation [18]. 
The carboxyl terminal portion of the receptor, also known as the endodomain, consists of 
seven transmembrane domains, three extracellular loops, three cytoplasmic loops, and a carboxyl 
terminal tail.  Cysteine residues in the first and second exoloops are thought to form an 
intramolecular disulfide bond that stabilizes the endodomain structure, as is the case with 
rhodopsin.  Two adjacent cysteines (Cys621, 622) are palmitoylated and embedded in the 
cytoplasmic face of the cell membrane, creating a fourth cytoloop.  Palmitoylated cysteine 
residues are not required for coupling of the LH/CG receptor to G proteins [14].   
 Analyses of similar G protein-coupled receptor transmembrane domains suggest that 
these helices are arranged in a counterclockwise direction when viewed extracellularly (Figure 1-
4) [24] [25]. 
 
2.  Hormone / Receptor Contact Sites 
 
 Photoaffinity labeling studies provided the first evidence that both subunits of hCG 
interact directly with the LH/CG receptor [26].  However, key hormone residues participating in 
receptor contact remain largely unidentified [3].   
 Many studies suggest that the C-terminus of the hCG α subunit and the β seatbelt loop 
play crucial roles in receptor binding and signal generation.  These segments are present in the 
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concave face of hCG, which is believed to be the receptor binding face [27].  Photoaffinity 
labeling studies using a peptide mimic of the C-terminus of hCG α have provided the only 
evidence of direct interaction between this region of the hormone and the receptor [27] [28].  
Interestingly, hCG homodimers lacking the β seatbelt or the C-terminal region of the α subunit 
have significant biological activity [29] [3].   
αL1, αL3, βL1, and βL3 have also been implicated in receptor binding [27].  In addition, 
synthetic peptides representing the β2 loop of hCG bind to and activate the receptor [30].  But 
hCG constructs containing hFSH β2 bind LH/CG receptors, not FSH receptors [31].  It is 
possible that the β2 loop of hCG is important for the overall structure of the hormone, which 
would account for it’s influence on receptor binding [3].   
Many studies have been devoted to identifying areas of the LH/CG receptor responsible 
for hormone binding.  Photoaffinity labeling experiments and studies using peptides representing 
different portions of the LH/CG receptor indicate that multiple hormone contact sites exist in the 
receptor.  The synthetic peptide study evaluated the ability of different regions of the LH/CG 
receptor to competitively inhibit binding of 125I-hCG to full-length membrane receptor.  Four 
regions of the receptor capable of interacting with hCG were identified:  LH/CG-R21-38, LH/CG-
R102-115, LH/CG-R253-272, and LH/CG-R573-583.  These regions represent the N-terminal region of 
the receptor, LRR4, the hinge region of the receptor, and exoloop 3, respectively [32]. 
Early photoaffinity labeling data pointed to the existence of at least three contact sites 
dispersed throughout the receptor:  one in the endodomain, and two in the exodomain.  Each of 
these three putative contact sites has a Lys residue to which hCG is affinity labeled [18].  
Mutagenesis studies coupled with photoaffinity labeling have yielded a wealth of information in 
regard to LH/CG receptor hormone contact sites.    
The LH/CG receptor exodomain binds hCG with high affinity [19] [20] [21] and contains 
eight to nine putative LRR sequences [16].  The beta-strand Leu/Ile-X-Leu/Ile motif is thought to 
make contact with hCG, based on structural similarity to ribonuclease inhibitors.  Alanine-
scanning mutagenesis of the beta-strand Leu/Ile residues in all LRRs of the human LH/CG 
receptor found that LRR2 and LRR4 are crucial for hCG binding [33].  Photoaffinity labeling 
results indicate that the N-terminal region of LRR4 interacts with hCG, preferentially the hCG α 
subunit.  The hCG/LRR4 complex interacts with exoloop 2, possibly generating the hormone 
signal [34].   
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The C-terminal flanking portion of the LRRs, known as the hinge region (Thr250-Gln268), 
also modulates signal generation in the receptor endodomain.  Several mutations in the hinge 
region result in a constitutively active LH/CG receptor, suggesting that the exodomain of the 
receptor constrains the endodomain [35] [36].  Photoaffinity labeling studies indicate that the 
hinge region specifically interacts with hCG, preferentially hCG α.  This interaction is inhibited 
by exoloop 2, pointing to the existence of an intimate relationship between the hinge region of 
the exodomain, exoloop 2 of the receptor endodomain, and hCG [36].   
Alanine-scanning of the N-terminal region of the LH/CG receptor identified three 
residues (Leu20, Cys22, and Gly24) crucial for hCG binding.  Substitution with alanine for any one 
of these residues abolished hormone binding [37].  A peptide mimic corresponding to Gly18-
Tyr36 of the receptor N-terminal region specifically photoaffinity labels both subunits of hCG, 
preferentially the α subunit.  These results indicate that the N-terminal region of the exodomain 
interacts with hCG.  Leu20, Cys22, and Gly24 in particular are crucial for hormone binding (Figure 
1-5) [38].   
 Based on the results of the mutagenesis studies, photoaffinity labeling experiments, and 
chimeric receptor analyses, a model of hCG’s interaction with the LH/CG receptor can be 
proposed.  The concave, front side of hCG interacts with the inner lining of the horseshoe or 1/3 
donut structure formed by the exodomain LRRs (Figure 1-6).  The hormone particularly interacts 
with LRR2 and LRR4 [36].  The N-terminal region of the receptor could potentially wrap around 
the hormone dimer, making contact with the convex, back surface of hCG [38].  In this model 
the exodomain of the LH/CG receptor traps the hormone, almost hugging hCG, in a manner that 
would certainly increase the binding affinity [36].  Experimental evidence suggests that the α 
subunit of hCG displaces the hinge region of the receptor from exoloop 2, “relaxing” the 
endodomain.  Ligand-induced conformational changes trigger signal transduction [39]. 
 
3.  Signal Generation and Transduction 
 
 Hormone action is induced when hormone binds to a receptor on the cell surface (Figure 
1-7).  However, only a fraction of occupied receptors actually generate a signal.  In some cases, 
the majority of hormone-bound receptors are endocytosed by the cell, and hormonal action is 
induced by occupied receptors remaining on the surface of the cell [18]. 
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 Sequence homology of the LH/CG receptor endodomain with other G protein-coupled 
receptors suggests that this receptor also interacts with G proteins.  Signaling of the LH/CG 
receptor is mediated by Gs, a G protein which is capable of stimulating adenylyl cyclase.  
Activated adenylyl cyclase converts adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP) [18] [3].   
LH/CG receptor activation also results in the production of inositol phosphates and an 
increase in the intracellular concentration of calcium ions [40].  Phospholipase C hydrolyzes 
phosphatidyl inositol resulting in the generation of inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol.  IP3 stimulates the release of calcium from the endoplasmic reticulum increasing 
the concentration of cytoplasmic calcium, and diacylglycerol activates protein kinase C [18]. 
Both the adenylyl cylcase and phospholipase C pathways are activated within minutes of 
LH/CG receptor activation.  Yet experimental evidence suggests that the two pathways operate 
independently of one another [18].  For example, mutant LH/CG receptors in which Lys583 is 
substituted with a variety of amino acids are no longer able to generate cAMP.  In contrast, 
Lys583 does not appear to play an essential role in the induction of inositol phosphates [41].  Also, 
the concentration of hCG which induces half of the maximum production (EC50) of inositol 
phosphates is 20 to 30 times higher than the EC50 value for cAMP synthesis.  Therefore, two 
distinct signaling pathways are activated by the LH/CG receptor [18]. 
 
C.  Goal of Thesis 
 
 The goal of this thesis work is to further describe the contact sites between the N-terminal 
region of the LH/CG receptor and hCG.  Photoaffinity labeling studies examine the contribution 
of individual residues in this region to hormone binding.  Enzymatic digestion experiments shed 
light on the regions of hCG that make contact with the N-terminal portion of the receptor.  These 
results provide insight into the mechanism of hormone/exodomain interaction.   
Approximately 16% of couples in the world suffer from infertility [27].  The receptor and 
hormone could potentially be used as fertility drugs as well as contraceptives.  Further 
understanding of hCG/receptor interactions is a crucial first step for the future design of 
pharmaceuticals. 
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Figure 1-1:  Computer model of hCG.  hCG α is shown in green, and hCG β in pink.  The 
seatbelt region of hCG β is shown in blue, wrapping around the α subunit stabilizing the 
heterodimer. 
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Figure 1-2:   The LH Receptor.  The amino acid sequence of the rat LHR is shown.  Vertical 
lines indicate exon divisions, hexagons enclose signal peptide amino acids, and amino acids 
comprising the mature peptide are within circles (Dufau, 1998) [14]. 
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Figure 1-3:  Computer model of the LH/CG receptor exodomain. The LH/CG receptor 
exodomain contains eight to nine copies of a motif known as the leucine-rich repeat.  Each LRR 
consists of an α helix (red), a turn (green), a β sheet (yellow), and another turn. 
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Figure 1-4:  Computer model of the LH/CG receptor endodomain.  The seven 
transmembrane helices, three exoloops, and three cytoloops of the receptor endodomain are 
shown from the top looking down (upper panel) and from the side (lower panel). 
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Figure 1-5:  N-terminal region residues of the LH/CG receptor crucial for hCG binding.  
Receptor residues Leu20, Cys22, and Gly24 are essential for hCG binding.  The N-terminal region 
of the receptor could wrap around the back of hCG, making contact with the convex face of the 
hormone heterodimer (Hong, 1998)[37], (Phang, 1998) [38]. 
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Figure 1-6:  Model for the interaction of the LH/CG receptor exodomain with hCG.  The 
concave, front side of hCG is thought to interact with the inner lining of the 1/3 donut structure 
formed by the exodomain LRRs. 
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Figure 1-7:  LH/CG receptor activation and signal transduction.  The receptor endodomain 
modulates hormone binding to the exodomain.  The hormone, exodomain, and endodomain 
complex undergo conformational adjustment activating the receptor and transducing the 
hormone signal.  Activation of adenylyl cyclase results in the production of cAMP.  Activation 
of PLC results in the generation of IP3 and diacyl glycerol. 
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CHAPTER TWO:  PHOTOAFFINITY LABELING STUDIES 
 
A.  Introduction 
 
 Since its introduction forty years ago [42], photoaffinity labeling has been an important 
technique for the characterization of binding sites including protein-protein interactions in 
biological systems.  In photoaffinity labeling experiments, a light-sensitive moiety is appended to 
a natural ligand. Upon activation with UV light, the modified ligand forms a very short-lived and 
highly reactive intermediate capable of reaction with residues of nearby molecules.  The covalent 
bond formed between the modified ligand and the neighboring molecule is resistant to cleavage 
under the denaturing conditions of SDS-PAGE. 
 Over the course of the past four decades, a variety of photophores have been developed.  
The majority of these reagents are diazo esters, aryl azides, or diazirines, which upon exposure to 
UV irradiation are converted to nitrenes or carbenes.  Unfortunately, nitrenes and carbenes react 
quickly with water, resulting in low efficiency photolabeling [43].  Benzophenone photoprobes 
have several key advantages over such reagents.  First, benzophenones are chemically more 
stable than diazo esters, aryl azides, and diazirines.  Benzophenones can also be manipulated in 
ambient light and activated at 350-360 nm, minimizing photolytic damage to proteins.  In 
addition, the excited state of the benzophenones, a triplet biradical, reacts preferentially with C-H 
bonds, even in the presence of water and bulk nucleophiles [44] [43].   
 Development of one benzophenone photophore in particular, the amino acid analog 4-
benzoyl-L-phenylalanine (Bpa) [45] (Figure 2-1), made possible a significant advance in the 
application of photoaffinity labeling to the study of peptide-protein interactions.  Bpa can be 
directly incorporated at a defined position into peptides by solid-phase synthesis, allowing for the 
examination of the relative importance of individual amino acids in protein-protein interactions.  
The advantages of photolabeling with benzophenone reagents, particularly Bpa, generally 
outweigh the disadvantages resulting from the introduction of the bulky, hydrophobic 
benzophenone moiety [44].  The photochemistry of benzophenone reagents is shown in Figure 2-
2. 
 Previous studies have shown that the amino-terminal region of the LH/CG receptor 
contacts both subunits of hCG.  In particular, three residues (Leu20, Cys22, and Gly24) were 
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found to be crucial for hormone binding [37] [38].  In this chapter, Bpa was used to continue 
investigating the interactions of the N-terminal region of the LH/CG-R with hCG.  Bpa has been 
directly incorporated at a defined position into peptides representing amino acids 17-36 of the 
LH/CG-R (Figure 2-3).  These peptides are radiolabeled with 125I and used in photoaffinity 
labeling studies.   
 
B.  Materials and Methods 
 
Materials 
  
 The hCG and deglycosylated hCG were supplied by the National Hormone and Pituitary 
Program (NIDDK, National Institutes of Health).  Denatured hCG was prepared by boiling hCG 
in 8 M urea and 0.1 M DTT for 30 minutes.  Peptide mimics including wild-type, mutant, and 
Bpa-containing LH/CG receptor peptides were synthesized by Genemed Synthesis, Inc. (San 
Francisco, CA). 
 
1.  Radioiodination of Peptides 
 
 1 mCi of Na125I in 10 µl of 0.1 M NaOH and 7 µl of chloramine T (1 mg/ml) in 0.1 M 
sodium phosphate (pH 7.5) were added to 30 µg of LHR peptide in 40 µl of 0.1 M sodium 
phosphate.  After 20 seconds, 7 µl of sodium metabisulfite (2.5 mg/ml) in 0.1 M sodium 
phosphate was introduced to terminate the iodination reaction.  Radioiodinated 125I-LHR solution 
was mixed with 60 µl of 16% sucrose solution in 0.1 M sodium phosphate and fractionated on a 
Sephadex Superfine G-10 column (0.6 x 15 cm) using 10 mM Na2HPO4 and 0.9% NaCl (pH 7.4) 
(PBS). 
 
2.  Photoaffinity Labeling of hCG 
 
hCG Concentration Dependent Experiments 
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Disposable glass tubes were siliconized under dimethyldichlorosilane vapor overnight 
and autoclaved.  The following solutions were sequentially introduced to siliconized glass tubes:  
32 µl of increasing concentrations of hCG in PBS, and 8 µl (100ng) of 125I-LHR peptide in PBS.  
Samples were incubated at 37°C for 90 minutes, then irradiated with a Mineralight R-52 UV 
lamp for 1 minute as described previously [46].  Immediately following UV exposure, samples 
were boiled for 3 minutes in 2% sodium dodecyl sulfate, 100 mM dithiothreitol, and 8 M urea.  
The solubilized samples were electrophoresed on 8-12% polyacrylamide gradient gels.  Gels 
were dried on filter paper, and exposed to PhosphorImager screens (Molecular Dynamics) 
overnight.  The exposed PhosphorImager screen was scanned on a model 860 Storm System 
Optical Scanner (Molecular Dynamics), and radioactive band intensity was determined using 
ImageQuant software (Molecular Dynamics).  
 
Peptide Concentration Dependent Experiments 
 
The following solutions were sequentially introduced to siliconized glass tubes:  32 µl of 
increasing concentrations of 125I-LHR peptide in PBS, and 8 µl (100ng) of hCG in PBS.  
Samples were incubated at 37°C for 90 minutes, then irradiated with a Mineralight R-52 UV 
lamp for indicated period of time.  Samples were processed as described above. 
 
UV Dependent Experiments 
  
The following solutions were sequentially introduced to siliconized glass tubes:  24 µl 
PBS, 100 ng of hCG in 8 µl of PBS, and 100 ng of  125I-LHR peptide in 8 µl of PBS.  Samples 
were incubated at 37°C for 90 minutes, then irradiated with a Mineralight R-52 UV lamp for 
increasing periods of time.  Samples were processed as described above. 
 
Competitive Inhibition of Photoaffinity Labeling of hCG 
 
 Competitive inhibition experiments were carried out as described for the photoaffinity 
labeling experiments, except that 8 µl (200ng) of hCG in PBS, and 8 µl (100ng) 125I-LHR 
  19
peptide in PBS were incubated with 24 µl of increasing concentrations of nonradioactive LHR 
peptide in PBS. 
 
C.  Results 
 
1.  Photoaffinity Scanning  
 
 The ability of each radioiodinated Bpa-substituted peptide to photoaffinity label hCG was 
assessed and compared in photoaffinity scanning studies (Figure 2-4).  Each of the five Bpa 
peptides was incubated with increasing concentrations of hCG and treated with UV for one 
minute.  While all peptides were able to photoaffinity label both the α and the β subunits of hCG 
to some extent, hLHR17-36(C22Bpa) clearly photolabeled the α subunit of hCG much more 
efficiently than any of the other Bpa peptides.  Labeling of hCG α by hLHR17-36(C22Bpa) was 
between 2.5-3.5 times greater than that of the other peptides.   
 The majority of the Bpa peptides preferentially labeled the α subunit of hCG.  Of the five 
peptides, hLHR17-36(R21Bpa) was the only one that labeled the β subunit of hCG as well or slightly 
better than the α subunit.  Photolabeling of the β subunit of hCG by hLHR17-36(R21Bpa), while 
interesting, was still much less efficient than photolabeling of hCG α by hLHR17-36(C22Bpa).  When 
combined at a molar ratio of 2:1 (peptide:hCG), hLHR17-36(C22Bpa) photolabeled approximately 
20% of the total hCG molecules (Figure 2-5).  The relatively high efficiency photoaffinity 
labeling of hCG α by hLHR17-36(C22Bpa) indicates that Cys22 could be the primary contact amino 
acid within the N-terminal region of the LH/CG receptor.  The specificity of this photolabeling 
was tested by changing the concentration of hLHR17-36(C22Bpa), and by increasing the duration of 
UV exposure. 
 
2.  hCG Concentration Dependent, UV Duration Dependent, and hLHR17-36(C22Bpa) 
Concentration Dependent Photoaffinity Labeling 
 
 When a constant amount of hLHR17-36(C22Bpa) was incubated with increasing amounts of 
hCG, the intensity of the labeled hCG α and hCG β bands gradually increased then plateaued 
(Figure 2-4, Figure 2-6, A).   The same pattern was seen when the converse experiment was 
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performed: a constant concentration of hCG was combined with increasing amounts of hLHR17-
36(C22Bpa) (Figure 2-6, C).  This indicates that hCG and hLHR17-36(C22Bpa) are interacting in a 
specific manner, dependent upon the concentration of each molecule. 
 As expected, in the absence of UV exposure photolabeling of hCG by hLHR17-36(C22Bpa) 
was negligible (Figure 2-6, B).  Gradually increasing the duration of UV exposure resulted in a 
steady increase in labeling of hCG α and hCG β, with a plateau in labeling seen after about 2 
minutes of UV irradiation.  Sustained maximum levels of labeling and preferential labeling of 
the α subunit of hCG indicate that the photoaffinity labeling is specific. 
 While these experiments illustrate that photoaffinity labeling of hCG by hLHR17-36(C22Bpa) 
is specific, they do not indicate whether or not this interaction is biologically specific.  To test 
this, a constant concentration of denatured hCG was incubated with increasing amounts of 
hLHR17-36(C22Bpa) (Figure 2-6, D).  hLHR17-36(C22Bpa) did not photolabel denatured hCG at all, 
despite the presence of high concentrations of the Bpa peptide.  This illustrates that the receptor 
peptide will only interact with biologically active hCG.  
 
3.  Photoaffinity Labeling in the Presence of Competitor Peptides 
 
 The ability of radioiodinated hLHR17-36(C22Bpa) to photolabel hCG in the presence of 
peptides representing other regions of the LH/CG receptor was assessed.  A constant 
concentration of hCG and a constant concentration of 125I-hLHR17-36(C22Bpa) were incubated with 
increasing concentrations of non-radioactive competitor peptides.  Those peptides which 
effectively inhibited photoaffinity labeling of hCG by 125I-hLHR17-36(C22Bpa) include hLHR17-
36(C22Bpa), hLHR17-36, rat LHR18-36 (rLHR18-36), hLHR96-115(C106Bpa), and hLHRExoloop 2 (Figure 2-7, 
Figure 2-9). 
 In contrast, hLHRExoloop 1, hLHRExoloop 3, hLHR246-269, and hLHR17-36(L20A-C22A-G24A) do not 
effectively inhibit photolabeling of hCG by 125I-hLHR17-36(C22Bpa) (Figure 2-8, Figure 2-9).  
hLHR17-36(L20A-C22A-G24A) (hLHRtriple mutant) is a peptide representing the N-terminal region of the 
LH/CG receptor in which the three residues previously found to be important for hCG binding 
(Leu20, Cys22, and Gly24) were substituted with Ala.  Previous studies indicate that this mutant 
peptide does not photolabel hCG [38].  As expected, hLHRtriple mutant is unable to inhibit 
photolabeling of hCG by 125I-hLHR17-36(C22Bpa). 
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 IC50 values, in this case the concentration of competitor peptide which reduces 
photolabeling of hCG by 50%, are a helpful tool in the analysis and comparison of competitor 
efficacy.  IC50 values for each competitor peptide are listed in Table 2-1.  A constant 
concentration of 1.12 µΜ 125I-hLHR17-36(C22Bpa) was used in the competition of labeling 
experiments.  hLHR17-36(C22Bpa) had an IC50 value of 1.28 µM for the α subunit of hCG, meaning 
that when this peptide was present at a molar ratio of 1:1 (competitor: 125I-hLHR17-36(C22Bpa)) 
photolabeling of hCG by 125I-hLHR17-36(C22Bpa) was reduced by 50%.  hLHR17-36, rLHR18-36, 
hLHRExoloop 2, and hLHR96-115(C106Bpa) are all also reasonably good competitors based on their IC50 
values.  Interestingly,  hLHR246-269 has a relatively low IC50 value, 1.44 µM.  However, despite 
very high concentrations, hLHR246-269 was unable to completely inhibit photolabeling of hCG by 
125I-hLHR17-36(C22Bpa).  hLHRExoloop 1 was also unable to completely inhibit photolabeling of hCG, 
but it’s IC50 value is much lower than that of hLHRExoloop 3.  Even at the highest concentrations 
tested, 29.03 µM and 19.85 µM respectively, hLHRExoloop 3 and hLHRtriple mutant were unable to 
reduce photolabeling of hCG by 50%. 
 Competition of labeling experiments were also performed using a different radioiodinated 
Bpa peptide, 125I-hLHR17-36(L20Bpa) (Figure 2-10, Figure 2-11, Figure 2-12, Table 2-2).  Results 
obtained using 125I-hLHR17-36(L20Bpa) corroborate the 125I-hLHR17-36(C22Bpa) data.  hLHR17-36(L20Bpa), 
hLHR17-36, rat LHR18-36 (rLHR18-36), hLHR96-115(C106Bpa), and hLHRExoloop 2 all were all effective 
inhibitors of hCG photolabeling, whereas hLHRExoloop 1, hLHRExoloop 3, hLHR246-269, and hLHR17-
36(L20A-C22A-G24A) were not.  Additionally, each of the five Bpa-substituted peptides were also able 
to inhibit photolabeling of hCG by 125I-hLHR17-36(L20Bpa) (Figure 2-13).  This indicates that these 
peptides all interact with hCG in a similar manner, and most likely share a similar structure. 
 
4.  Photoaffinity Labeling of Deglycosylated hCG 
 
 As mentioned earlier, deglycosylated hCG acts as an LH/CG receptor antagonist.  
Deglycosylated hCG binds the LH/CG receptor with an affinity similar to that of hCG, but is 
unable to elicit hormone action [9] [10] [11].  Affinity labeling studies found that deglycosylated 
hCG was cross-linked to a 34 kDa component of the LH/CG receptor, whereas hCG was 
consistently cross-linked to a 24 kDa receptor component [47].  This difference in receptor 
binding could be responsible for the success or failure of signal transduction [47] [11]. 
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 Studies assessing the ability of hLHR17-36(G18Bpa),  hLHR17-36(A19Bpa), hLHR17-36(L20Bpa), 
hLHR17-36(R21Bpa), and hLHR17-36(C22Bpa) to photolabel deglycosylated hCG indicate that the N-
terminal region of the LH/CG receptor interacts with deglycosylated hCG (Figure 2-14, A).  The 
efficiency of photolabeling varied based on the position of the Bpa photophore, with hLHR17-
36(C22Bpa) labeling both subunits of deglycosylated hCG better than any of the other Bpa peptides.  
Photolabeling experiments in which a constant concentration of radioiodinated hLHR17-36(C22Bpa) 
was incubated with increasing amounts of deglycosylated hCG, show saturation of labeling and 
therefore specificity (Figure 2-14, B).  Interestingly, all of the Bpa peptides preferentially 
photolabeled the β subunit of deglycosylated hCG.  Based on these results, the N-terminal region 
of the LH/CG receptor does not appear to be involved in the differential binding seen with hCG 
and deglycosylated hCG. 
 
D.  Conclusions 
 
Photoaffinity scanning results clearly show that hLHR17-36(C22Bpa) labels hCG α with the 
highest efficiency.  Interestingly, photolabeling of the α subunit increased slightly with closer 
proximity to the Cys22 position.  In other words, if the Bpa peptides were listed in order of hCG 
α subunit labeling ability, from lowest to highest, that list would look like this:  hLHR17-
36(G18Bpa), hLHR17-36(A19Bpa), hLHR17-36(L20Bpa), hLHR17-36(R21Bpa), and hLHR17-36(C22Bpa).  This 
pattern does not appear to hold true for photolabeling of the β subunit. 
The majority of the Bpa peptides preferentially labeled the α subunit of hCG.  Of the five 
peptides, hLHR17-36(R21Bpa) was the only one that labeled the β subunit of hCG as well or slightly 
better than the α subunit.  The spatial arrangement of the Bpa photophore in this position could 
be one possible explanation.  When in this position, the benzophenone moiety could be 
approximately the same distance from both the α subunit and the β subunit of hCG, allowing for 
photolabeling of both subunits with essentially the same efficiency. 
The ability of hLHR17-36(C22Bpa), hLHR17-36, rLHR18-36, hLHR96-115(C106Bpa), and 
hLHRExoloop 2 to inhibit photolabeling of hCG by 125I-hLHR17-36(C22Bpa) could be occurring through 
either of two inhibitory mechanisms:  direct competition or allosteric inhibition.   Receptor 
peptides could potentially directly compete with 125I-hLHR17-36(C22Bpa) for interaction with the 
same site on hCG.  In this scenario, the competitor peptide prevents the Bpa peptide from 
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labeling hCG by physically occupying the binding site.  Another possibility is that the non-
radioiodinated peptide could interact with a different portion of hCG, causing a change in 
conformation of the hormone which prevents 125I-hLHR17-36(C22Bpa) from photolabeling hCG.   
The results of experiments designed to determine the mechanism of inhibition by each of 
these receptor peptides were inconclusive.  However, it seems likely that hLHR17-36(C22Bpa), 
hLHR17-36, and rLHR18-36 directly inhibit 125I-hLHR17-36(C22Bpa) labeling of hCG.  The fact that 
hLHR17-36 is able to inhibit the photolabeling indicates that 125I-hLHR17-36(C22Bpa) is a good mimic 
of the wild-type N-terminal portion of the receptor.  hLHRExoloop 2 could inhibit photolabeling by 
125I-hLHR17-36(C22Bpa) either directly or allosterically, either mechanism is plausible.  hLHR96-
115(C106Bpa) is a Bpa peptide representing LRR 4.  Computer modeling studies of the LH/CG 
receptor suggest that eight to nine LRRs assume a one-third doughnut structure which lines the 
inside face of the receptor exodomain, interacting with the concave face of hCG.  The N-terminal 
portion of the receptor is thought to wrap around the back of hCG, making contact with the 
convex face of the hormone dimer [38].  While it is possible that hLHR96-115(C106Bpa) could 
directly compete with 125I-hLHR17-36(C22Bpa) for hCG binding, the structure of the receptor 
exodomain favors a scenario where the two regions of the receptor interact with opposite faces of 
the hormone.  Whatever the mechanism of inhibition, these results suggest that an intimate 
relationship exists between the N-terminal region of the receptor, exoloop 2, and LRR 4. 
These experimental findings suggest that of the three residues previously found to be 
crucial for hCG binding, Cys22 may be the primary contact amino acid.  Photoaffinity labeling of 
hCG by hLHR17-36(C22Bpa) was shown to be saturable and specific.  hLHR17-36(C22Bpa) did not 
photolabel denatured hCG, indicating that the interaction is also biologically specific.  
Photolabeling of hCG by hLHR17-36(C22Bpa) was inhibited by hLHR17-36, indicating that the Bpa-
substituted peptide is a good mimic of the wild-type N-terminal region of the receptor. 
The next set of experiments were designed to determine where the corresponding contact 
site(s) in hCG are located. 
αð subunit βð subunit 
Cold Peptide IC50 (µðM) IC50 (µðM)
hLHR17-36(C22Bpa) 1.28 1.1
hLHR17-36 2.07 2.04
rLHR18-36 2.16 1.99
hLHR96-115(C106Bpa) 2.48 2.48
hLHRExoloop2 1.32 1.19
hLHRExoloop1 2.95 3.8
hLHRExoloop3 > 29.03 > 29.03
hLHR246-269 1.44 2.17
hLHRtriple mutant > 19.85 > 19.85
Table 2-1:  IC50 values of competitor peptides.  The concentration of each competitor 
peptide required to inhibit 125I-hLHR17-36(C22Bpa) photoaffinity labeling of hCG by 50% 
was calculated.  Even at the highest concentrations tested, 29.03 µM and 19.85 µM 
respectively, hLHRExoloop 3 and hLHR17-36(L20A-C22A-G24A) (hLHRtriple mutant) were unable 
to reduce photolabeling of hCG by 50%.
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αð subunit βð subunit 
Cold Peptide IC50 (µðM) IC50 (µðM)
hLHR17-36(L20Bpa) 2.1 1.67
hLHR17-36 2 2.4
rLHR18-36 1.08 1.64
hLHR96-115(C106Bpa) 2.5 1.26
hLHRExoloop2 2.12 1.99
hLHRExoloop1 2.95 2.28
hLHRExoloop3 > 29.03 > 29.03
hLHR246-269 N/A N/A
hLHRtriple mutant 13.52 17.59
Table 2-2:  IC50 values of competitor peptides.  The concentration of each competitor 
peptide required to inhibit 125I-hLHR17-36(L20Bpa) photoaffinity labeling of hCG by 50% 
was calculated.  Even at the highest concentration tested (29.03 µM) hLHRExoloop 3 was
unable to reduce photolabeling of hCG by 50%.  Inhibition of photolabeling by hLHR246-269
was not maintained at a level under 50%, therefore no IC50 value could be calculated.
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Figure 2-1:  Structure of 4-benzoyl-L-phenylalanine (Bpa).  Bpa has an amino group and a 
carboxyl group, allowing for direct incorporation at a defined position into a peptide by solid-
phase synthesis [44]. 
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Figure 2-2:  Photochemistry of Benzophenone Photophore.  Absorption of a photon at 
approximately 350 nm results in the formation of a diradical (1).  The electophilic oxygen 
interacts with weak C-H bonds (2), resulting in hydrogen abstraction.  The ketyl (3) and alkyl (4) 
radicals recombine to form a new C-C bond (5).  The diradical is only able to attack 
geometrically accessible C-H bonds [44].
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LH/CG-R17-36 
 
D G A L R C P G P T A G L T R L S L A Y 
 
 
 
D       Bpa  A  L  R  C     (G18Bpa) 
D  G  Bpa  L  R  C     (A19Bpa) 
D  G  A  Bpa  R  C     (L20Bpa) 
D  G  A  L  Bpa  C     (R21Bpa) 
D  G  A  L  R  Bpa (C22Bpa) 
 
 
 
 
 
 
 
 
Figure 2-3:  Bpa substituted peptides.  Peptides corresponding to the N-terminal region of the 
LH/CG-R were synthesized in which 5 amino acids were individually replaced with Bpa, a 
photoactivatable reagent.  This allows for the analysis of each individual amino acid’s interaction 
with hCG. 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 6 7 8
125I-G18Bpa(mM) 1.10 1.10 1.10 1.10 1.10 1.10 1.10 1.10
hCG (mM) 0 0.03 0.07 0.13 0.26 0.53 1.05 2.11
β  
α  
1 2 3 4 5 6 7 8
125I-A19Bpa(mM) 1.11 1.11 1.11 1.11 1.11 1.11 1.11 1.11
hCG (mM) 0 0.03 0.07 0.13 0.26 0.53 1.05 2.11
α  
 β
1 2 3 4 5 6 7 8
125I-R21Bpa(mM) 1.15 1.15 1.15 1.15 1.15 1.15 1.15 1.15
hCG (mM) 0 0.03 0.07 0.13 0.26 0.53 1.05 2.11
α  
 β
1 2 3 4 5 6 7 8
125I-C22Bpa(mM) 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12
hCG (mM) 0.015 0.03 0.07 0.13 0.26 0.53 1.05 2.11
 β
α  
1 2 3 4 5 6 7 8
125I-L20Bpa(mM) 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13
hCG (mM) 0 0.03 0.07 0.13 0.26 0.53 1.05 2.11
 β
α  
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Figure 2-4:  Photoaffinity scanning data.  Each of the five Bpa-substituted peptides was 
incubated with increasing concentrations of hCG and treated with UV for 1 minute as described 
in “Materials and Methods”.  Following electrophoresis, gels were dried and exposed to 
PhosphorImager screens (Molecular Dynamics) overnight.  The imaging screens were scanned 
on a model 860 Storm System Optical Scanner (Molecular Dynamics), and radioactive band 
intensity was measured using ImageQuant software (Molecular Dynamics).  The bar graphs 
show the percent radioactivity of the α band and the β band in a gel lane.  These results indicate 
that hLHR17-36(C22Bpa) photolabels hCG much more efficiently than any of the other Bpa peptides. 
 
Figure 2-5:  Photoaffinity scanning summary.  The maximum percent of hCG that was 
photolabeled by each Bpa peptide was calculated using the molar ratio of peptide to hormone in 
Lane 6 of Figure 2-4.  hLHR17-36(C22Bpa) labels the α subunit of hCG much more efficiently 
than any of the other 4 Bpa-substituted peptides.
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1 2 3 4 5 6 7 8
hCG (mM) 0.015 0.03 0.07 0.13 0.26 0.53 1.05 2.11
125I-C22Bpa(mM) 0.56 0.56 0.56 0.56 0.56 0.56 0.56 0.56
UV (minutes) 2 2 2 2 2 2 2 2
1 2 3 4 5 6 7 8
hCG (mM) 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07
125I-C22Bpa(mM) 1.12 1.12 1.12 1.12 1.12 1.12 1.12 1.12
UV (minutes) 0 0.5 1 1.5 2 2.5 3 4
1 2 3 4 5 6 7 8
hCG (mM) 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07
125I-C22Bpa(mM) 0.14 0.28 0.56 1.12 2.25 3.37 4.50 6.75
UV (minutes) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
1 2 3 4 5 6 7 8
Denatured hCG (mM) 0.07 0.07 0.07 0.07 0.07 0.07 0.07 0.07
125I-C22Bpa(mM) 0.14 0.28 0.56 1.12 2.25 3.37 4.50 6.75
UV (minutes) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
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Figure 2-6:  hCG concentration dependent, 125I-hLHR17-36(C22Bpa) concentration dependent, 
and UV duration dependent photoaffinity labeling.  A)  A constant concentration of 125I-
hLHR17-36(C22Bpa) was incubated with increasing concentrations of hCG and exposed to UV 
irradiation as indicated.  B)  Constant concentrations of hCG and 125I-hLHR17-36(C22Bpa) were 
incubated and irradiated with UV for increasing periods of time.  C)  A constant concentration of 
hCG was incubated with increasing concentrations of 125I-hLHR17-36(C22Bpa) and exposed to UV 
irradiation as indicated.  D)  A constant concentration of denatured hCG was incubated with 
increasing concentrations of 125I-hLHR17-36(C22Bpa) and exposed to UV irradiation as indicated.  
All gels were processed as described in the legend to Figure 2-4. 
 
β  
α  
hLHR17-36(C22Bpa)
β  
hLHR17-36
α  
rLHR18-36
β  
α  
β  
 	               0      25     50    100   200   400   800  1600
	 	 	 Unlabeled Peptide (ng)
hLHRExoloop 2
α  
hLHR96-115(C106Bpa)
β  
α  
34
  35
Figure 2-7:  Inhibition of photoaffinity labeling by LHR peptides.  A constant concentration 
of hCG (0.13 µΜ) and a constant concentration of 125I-hLHR17-36(C22Bpa) (1.12 µΜ) were 
incubated with increasing concentrations of non-radioactive competitor peptides representing 
various regions of the LH/CG receptor and exposed to UV irradiation for 2 minutes.  Gels were 
processed as described in the legend to Figure 2-4.  Competitor peptides included in this figure 
effectively inhibited photoaffinity labeling of hCG by 125I-hLHR17-36(C22Bpa). 
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Figure 2-8:  Inhibition of photoaffinity labeling by LHR peptides.  A constant concentration
of hCG (0.13 µM) and a constant concentration of 125I-hLHR17-36(C22Bpa) (1.12 µM) were 
incubated with increasing concentrations of non-radioactive competitor peptides and exposed
to UV irradiation for 2 minutes.  Gels were processed as described in the legend to Figure 2-4.
Competitor peptides included in this figure do not effectively inhibit photoaffinity labeling of 
hCG by 125I-hLHR17-36(C22Bpa).
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Figure 2-9:  Graphical representation of 125I-hLHR17-36(C22Bpa) photoaffinity labeling 
inhibition experiments.  The percent labeling of the α and β subunits were plotted against 
increasing concentrations of LHR peptides.
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Figure 2-10: Inhibition of photoaffinity labeling by LHR peptides.  A constant concentration 
of hCG (0.13 µΜ) and a constant concentration of 125I-hLHR17-36(L20Bpa) (1.13 µΜ) were 
incubated with increasing concentrations of non-radioactive competitor peptides representing 
various regions of the LH/CG receptor and exposed to UV irradiation for 1.5 minutes.  Gels were 
processed as described in the legend to Figure 2-4.  Competitor peptides included in this figure 
effectively inhibited photoaffinity labeling of hCG by 125I-hLHR17-36(L20Bpa).  
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Figure 2-11:  Inhibition of photoaffinity labeling by LHR peptides.  A constant concentration
of hCG (0.13 µM) and a constant concentration of 125I-hLHR17-36(L20Bpa) (1.13 µM) were 
incubated with increasing concentrations of non-radioactive competitor peptides and exposed
to UV irradiation for 1.5 minutes.  Gels were processed as described in the legend to Figure 2-4.
Competitor peptides included in this figure do not effectively inhibit photoaffinity labeling of 
hCG by 125I-hLHR17-36(L20Bpa).
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Figure 2-12:  Graphical representation of 125I-hLHR17-36(L20Bpa) photoaffinity labeling 
inhibition experiments.  The percent labeling of the α and β subunits were plotted against 
increasing concentrations of LHR peptides.
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Figure 2-13:  Inhibition of photoaffinity labeling by Bpa peptides.  A constant concentration 
of hCG (0.13 µM) and a constant concentration of 125I-hLHR17-36(L20Bpa) (1.13 µM) were  
incubated with increasing concentrations of non-radioactive Bpa peptides and exposed 
to UV irradiation for 1.5 minutes.  Gels were processed as described in the legend to Figure 2-4. 
All 5 Bpa peptides effectively inhibit photoaffinity labeling of hCG by 125I-hLHR17-36(L20Bpa). 
 
  
1 2 3 4 5 6 7 8
125I-hLHR17-36(C22Bpa) (µðM) 0.56 0.56 0.56 0.56 0.56 0.56 0.56 0.56
Deglycosylated hCG (µM) 0     0.04      0.08      0.16      0.32      0.64        1.28        2.56
UV (min) 2 2 2 2 2 2 2 2
Figure 2-14:  Photoaffinity labeling of deglycosylated hCG.  A)  Each of the 5 Bpa 
substituted peptides was incubated with deglycosylated hCG and treated with UV for
2 minutes.  B)  A constant concentration of 125I-hLHR17-36(C22Bpa) was incubated with
increasing concentrations of deglycosylated hCG and exposed to UV irradiation for 2
minutes.  Gels were processed as described in the legend to Figure 2-4.  All 5 of the 
Bpa peptides photoaffinity labeled deglycosylated hCG, with varying degrees of 
efficiency.  Photoaffinity labeling of deglycosylated hormone by 125I-hLHR17-36(C22Bpa)
is saturable.    
  G18Bpa	  A19Bpa	  L20Bpa	 R21Bpa      C22Bpa
1 3 5 7 9
125I-hLHR17-36(Bpa) (µΜð) 1.1 1.11 1.13 1.15 1.12
Deglycosylated hCG (µðM) 0.57 0.57 0.57 0.57 0.57
UV (minutes) 2 2 2 2 2
A
B
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CHAPTER THREE:  ENZYMATIC AND CHEMICAL DIGESTION STUDIES 
 
A.  Introduction 
 
 Results of photoaffinity labeling studies suggest that Cys22 may be the primary contact 
amino acid in the N-terminal region of the LH/CG receptor.  The next series of experiments were 
designed to determine which fragment of hCG is photoaffinity labeled by the hLHR17-36(C22Bpa) 
peptide.  Enzymatic digestion and chemical cleavage of the hCG/ hLHR17-36(C22Bpa) complex were 
the techniques used to answer this question. 
 
B.  Materials and Methods 
 
Materials 
 
 The hCG, hCG β, and deglycosylated hCG were supplied by the National Hormone and 
Pituitary Program (NIDDK, National Institutes of Health).  Bpa substituted LH/CG receptor 
peptides were synthesized by Genemed Synthesis, Inc. (San Francisco, CA).  Endoproteinase 
Glu-C, neuraminidase, and O-glycosidase were purchased from Roche.  Cyanogen bromide 
(CNBr) was purchased from Sigma.  PNGase F was purchased from New England Biolabs.   
 
1.  Radioiodination of hCG or deglycosylated hCG 
 
1 mCi of Na125I in 10 µl of 0.1 M NaOH and 7 µl of chloramine T (1 mg/ml) in 0.1 M 
sodium phosphate (pH 7.5) were added to 5 µg hCG or deglycosylated hCG in 40 µl of 0.1 M 
sodium phosphate.  After 20 seconds, 7 µl of sodium metabisulfite (2.5 mg/ml) in 0.1 M sodium 
phosphate was introduced to terminate the iodination reaction.  Radioiodinated 125I-hCG solution 
was mixed with 60 µl of 16% sucrose solution in 0.1 M sodium phosphate and fractionated on a 
Sephadex Superfine G-50 column (0.6 x 15 cm).  0.1% gelatin in 10 mM Na2HPO4 and 0.9% 
NaCl (pH 7.4) (PBS) was used to pre-equilibrate the column and elute the sample.   
 
2.  Radioiodination of hCG β 
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 Iodination of hCG β was carried out as described for radioiodination of hCG or 
deglycosylated hCG, except that a Sephadex Superfine G-25 column was used for sample 
fractionation. 
 
3.  Enzymatic Digestion with Endoproteinase Glu C 
 
 The following solutions were sequentially introduced to siliconized glass tubes:  25 µl of 
10mM PBS, 800 ng of hCG or 700 ng of deglycosylated hCG in 10 µl 10mM PBS, and 50 ng of 
125I-hLHR17-36(Bpa) in 5 µl 10mM PBS.  Samples were incubated at 37ºC for 90 minutes, then 
irradiated with a Mineralight R-52 UV lamp for 1.5 minutes.  Samples were boiled for 3 minutes 
in 0.1M urea and 5mM DTT.  After cooling to room temperature, samples were transferred to 
siliconized 0.65 ml Eppendorf tubes.  6% Endoproteinase Glu C was added as indicated.  
Following an 18 hour incubation at 25ºC, individual sample volumes were reduced to 
approximately 12 µl in a vacuum centrifuge on medium heat setting (43ºC).  Samples were 
boiled for 3 minutes in 2% sodium dodecyl sulfate, 100mM dithiothreitol, and 8M urea.  The 
solubilized samples were electrophoresed on 15% polyacrylamide single gradient gels.  Gels 
were dried on filter paper, and exposed to PhosphorImager screens (Molecular Dynamics) 
overnight.  The exposed PhosphorImager screen was scanned on a model 860 Storm System 
Optical Scanner (Molecular Dynamics), and radioactive band intensity was determined using 
ImageQuant software (Molecular Dynamics). 
 
4.  Chemical Cleavage with CNBr 
 
 First, the 6 samples that were photolabeled were prepared.  The following solutions were 
sequentially introduced to siliconized 0.65 ml Eppendorf tubes:  20 µl PBS, 800 ng of hCG in 10 
µl PBS, and 50 ng or 100 ng of 125I-hLHR17-36(C22Bpa) in 10 µl 10mM PBS.  Samples were 
incubated at 37ºC for 90 minutes, then irradiated with a Mineralight R-52 UV lamp for 2 
minutes.  Samples were completely dried in a vacuum centrifuge on medium heat setting (43ºC).  
50 µl 70% formic acid or 50 µl 70% TFA was added to each tube as indicated.  1 µl 125I-hCG or 
125I-hCG β were added as indicated to tubes not containing photolabeled hCG.  A small crystal 
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of CNBr was added to each tube, and swirled gently to dissolve.  Samples were incubated at 
room temperature for 12 hours in the dark.  Reactions were quenched by evaporating the formic 
acid or TFA in a vacuum centrifuge (43ºC) after diluting the acid to 7% with water.  Digests 
were dried completely in the vacuum centrifuge.  10 µl PBS was added to each tube.  Samples 
were boiled for 3 minutes in 2% sodium dodecyl sulfate, 100mM dithiothreitol, and 8M urea.  
The solubilized samples were electrophoresed on a 15% polyacrylamide single gradient gel, and 
processed as described above. 
 
5.  Deglycosylation of hCG 
 
19 µl 20mM sodium phosphate (pH 7.2) was added to each siliconized 0.65 ml 
Eppendorf tube.  1 µl 125I-hCG or 125I-hCG β were added as indicated.  Samples were denatured 
by boiling for 10 minutes in 0.5% SDS and 1% β-mercaptoethanol.  1% NP-40 was then added 
to each tube.  After allowing the samples to cool completely, 0.056 mU neuraminidase, 0.069 
mU O-glycosidase, and 27.8 units of PNGase F were added to each tube as indicated.  Samples 
were incubated at 37ºC for 18 hours.  Individual sample volumes were reduced to approximately 
10 µl in a vacuum centrifuge on medium heat setting (43ºC).  Samples were boiled for 3 minutes 
in 2% sodium dodecyl sulfate, 100mM dithiothreitol, and 8M urea.  The solubilized samples 
were electrophoresed on a 12.5% polyacrylamide single gradient gel, and processed as described 
above. 
 Alternatively, samples were prepared as described but denatured by boiling for 10 
minutes in 0.1% SDS and 10mM DTT.  The samples were cooled to room temperature and 
deglycosylation enzymes were added as indicated. 
 
6.  In-gel Digestion of Photolabeled hCG α and Photolabeled hCG β 
 
 The following solutions were sequentially introduced to siliconized 0.65 ml Eppendorf 
tubes:  10 µg hCG in 20 µl sodium phosphate (pH 7.2) and 1.76 µg 125I- hLHR17-36(C22Bpa) in 40 
µl sodium phosphate.  Samples were incubated at 37ºC for 90 minutes, then irradiated with a 
Mineralight R-52 UV lamp for 2 minutes.  Samples were denatured by boiling for 10 minutes in 
0.5% SDS and 1% β-mercaptoethanol.  1% NP-40 was then added to each tube.  After allowing 
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the samples to cool completely, 5 mU neuraminidase was added to each tube.  Samples were 
incubated at 37ºC for 12 hours.  0.1 mU O-glycosidase, and 250 units of PNGase F were added 
to each tube, and samples were incubated at 37ºC for 28 hours.  Individual sample volumes were 
reduced to approximately 40 µl in a vacuum centrifuge on medium heat setting (43ºC).  Samples 
were boiled for 3 minutes in 2% sodium dodecyl sulfate, 100mM dithiothreitol, and 8M urea.  
The solubilized samples were electrophoresed on a 12.5% polyacrylamide single gradient gel.  
The gel was stained with Coomassie Blue (Bio-Rad) and destained until the background level of 
stain was acceptable.  Two bands representing photolabeled, deglycosylated hCG β were excised 
from the gel using a clean razorblade, chopped up into small cubes and combined in a siliconized 
1.5 ml Eppendorf tube.  This process was repeated for the other two photolabeled, 
deglycosylated hCG β bands and for both sets of photoaffinity labeled, deglycosylated hCG α 
bands.  In-gel digestions of hCG α and hCG β were performed using CNBr on one sample set, 
and Glu C on the other. 
 Excised gel pieces were rehydrated in 100mM NH4HCO3.  After 15 minutes, an equal 
volume of acetonitrile was added and tubes were vortexed for 15 minutes.  All liquid was 
removed and acetonitrile was added to shrink the gel pieces.  All liquid was removed and gel 
pieces were dried down in a vacuum centrifuge (43ºC).  The gel pieces were then incubated in 
10mM dithiothreitol/100mM NH4HCO3 for 60 minutes at 56ºC to reduce the proteins.  After 
allowing the samples to cool to room temperature, the gel pieces were spun down and excess 
liquid was removed.  55mM iodoacetamide/100mM NH4HCO3 was used to alkylate the proteins.  
Samples were incubated in the iodoacetamide solution for 45 minutes in the dark.  All liquid was 
removed, gel pieces were shrunk with acetonitrile, and gel particles were dried down in a 
vacuum centrifuge (43ºC).   
Samples designated for cleavage by CNBr were rehydrated in 70% formic acid.  A small 
crystal of CNBr was added to each tube.  Samples reserved for Glu C digestion were rehydrated 
in a digestion solution consisting of 25mM NH4HCO3 (pH 7.8) and 10% Glu C by weight.  
Samples were incubated overnight at room temperature, in the dark.   
Next, peptides were extracted from the gel particles.  Samples were incubated at 37ºC for 
15 minutes with shaking.  Gel particles were spun down, and the supernatant was collected and 
saved.  The extraction was repeated twice with a 5% formic acid:acetonitrile solution.  All 
supernatants were combined and dried down in a vacuum centrifuge.   
  49
100 µl of water was added to each tube and samples were dried down again.  Each digest 
was solubilized in 40µl 20mM sodium phosphate.  Samples were boiled for 3 minutes in 2% 
sodium dodecyl sulfate, 100mM dithiothreitol, and 8M urea.  The solubilized samples were 
electrophoresed on a 15% polyacrylamide single gradient gel, and processed as described above. 
 
C.  Results 
 
1.  Enzymatic Digestion of Photoaffinity Labeled Hormone by Endoproteinase Glu C 
 
The ability of Endoproteinase Glu C to cleave photolabeled hCG was evaluated (Figure 
3-1).  Each of the five Bpa peptides was incubated with hCG and treated with UV for 90 
seconds.  Following denaturation, samples were incubated with Glu C for 18 hours.   
 A faint band located approximately half-way between photolabeled hCG α and free 125I-Bpa 
peptide can be seen on the autoradiograph.  This band is located in the same position for each of 
the Bpa peptides, suggesting that the same fragment of hCG was photolabeled by each Bpa-
substituted peptide.  These results further confirm the specificity of the photoaffinity labeling.  
However, the vast majority of the photolabeled hCG β and photolabeled hCG α molecules 
remain intact.  This indicates that cleavage of the hCG/ hLHR17-36(Bpa) complex by Glu C under 
these conditions was relatively inefficient.   
 The ability of Endoproteinase Glu C to cleave photolabeled deglycosylated (dg) hCG was 
also assessed (Figure 3-2).  Immediately below the band corresponding to photolabeled dghCG 
α, a faint band representing a photolabeled fragment of dghCG can be seen.  Just above the free 
125I-Bpa peptide band, a second band even fainter than the first, can also be detected.  The 
presence of these two bands in the same position for each of the Bpa peptides indicates that the 
same fragments of dghCG were photolabeled by each of the five Bpa-substituted peptides.  
Cleavage of the dghCG/ hLHR17-36(Bpa) complex by Glu C under these conditions also appears to 
have been inefficient.   
 
2.  Chemical Cleavage of Photoaffinity Labeled Hormone by Cyanogen Bromide 
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The ability of CNBr to cleave photolabeled hCG was evaluated (Figure 3-3).  125I-
hLHR17-36(C22Bpa) was incubated with hCG and exposed to UV irradation for 2 minutes.  Samples 
were dried down then solubilized in either formic acid or TFA, and incubated for 12 hours with 
CNBr.  Two bands representing photolabeled fragments of hCG can be seen in Figure 3-3, B.  
The majority of photolabeled hCG α appears to have been cleaved by CNBr, consistent with 
cleavage of 125I-hCG seen in gel lanes two and three of Figure 3-3, A.  Cleavage of photolabeled 
hCG β and 125I-hCG β was less efficient (Figure 3-3, B:  lanes 9,10,12,13; Figure 3-3, A:  lanes 
5,6).  Overall, these results indicate that cleavage of the hCG/ hLHR17-36(C22Bpa) complex by 
CNBr was more efficient than digestion by Glu C. 
 
3.  Enzymatic Deglycosylation of Radioiodinated hCG 
 
 In an attempt to further improve enzymatic and chemical cleavage efficiency, and also to 
facilitate hCG fragment identification, hCG was deglycosylated.  Deglycosylation enzymes used 
include neuraminidase, PNGase F, and O-glycosidase.  Neuraminidase cleaves sialic acid, and 
PNGase F and O-glycosidase hydrolyze N-acetylglucosaminylasparagine and N-
acetylgalactosaminylserine/threonine linkages, respectively [48].   
The efficacy of deglycosylation by neuraminidase, PNGase F, and O-glycosidase 
following two different methods of denaturing hCG was examined (Figure 3-4).  Prior to the 
addition of deglycosidases, 125I-hCG and 125I-hCG β were denatured by boiling for 10 minutes in 
0.1% SDS and 10mM DTT (Figure 3-4, A).  As evidenced by the lack of band shifting, neither 
125I-hCG α or 125I-hCG β were deglycosylated.  In contrast, when 125I-hCG and 125I-hCG β were 
denatured by boiling for 10 minutes in 0.5% SDS and 1% β-mercaptoethanol, followed by the 
addition of 1% NP-40 (a non-ionic detergent), bands representing each hormone subunit shifted 
significantly (Figure 3-4, B).  This indicates that carbohydrate moieties were effectively 
removed. 
 
4.  CNBr and Glu C Digestion of Photolabeled hCG α and Photolabeled hCG β 
 
 One problem with the in-tube digestions of photoaffinity labeled hormone is the difficulty 
in identification of the photolabeled hCG fragment.  It is hard to determine with certainty which 
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subunit the photolabeled hCG fragment was derived from, let alone the amino acid sequence of 
the fragment.  Separate, in-gel digestions of photolabeled hCG α and photolabeled hCG β solved 
this problem. 
 hCG was photoaffinity labeled with 125I-hLHR17-36(C22Bpa), deglycosylated, and 
electrophoresed.  Bands representing photolabeled, deglycosylated hCG α and photolabeled, 
deglycosylated hCG β were cut from the gel and digested separately with either CNBr or Glu C 
(Figure 3-5).  The molecular weight of the photolabeled fragments in gel lanes 2, 3, 4, and 5 
were determined according to the migration of 125I-hCG, 125I-hCG β, and 125I-hLHR17-36(C22Bpa).  
The migration coefficient of each of these molecular weight markers was calculated and used to 
construct a standard graph.  This graph was then used to estimate the molecular weight of the 
photolabeled hCG fragments. 
 Based on this analysis, the fragment of photolabeled, CNBr-cleaved hCG α in gel lane 2 
was assigned a mass range of 1.9 – 5.5 kd (kilodaltons).  Complete CNBr digestion of hCG α 
generates four fragments (Figure 3-6).  The first fragment, hCG α1-29, has a mass of 1998 daltons 
(2112 daltons when iodoacetamide is used as an alkylating agent).  This is a close match to the 
estimated fragment mass of 1.9 kd.  If the cleavage site following Met29 were missed by CNBr, 
the resulting fragment would have a mass of 5413 daltons, close to the 5.5 kd estimate of the 
hCG α fragment in lane 2.  Masses of the third and fourth CNBr-generated fragments, hCG α48-
71 and hCG α72-92, are 2726 and 2543 daltons respectively.  Neither of these matches the 
estimated mass of the fragment. 
 The smaller fragment of photolabeled, CNBr-cleaved hCG β in lane 3 was assigned a 
mass of 4.8 kd.  The other band corresponds to photolabeled, deglycosylated, and alkylated hCG 
β.  There is only one cleavage site for CNBr in the β subunit of hCG (Figure 3-6).  The first 
fragment, hCG β1-41, has a mass of 4672 daltons when alkylated with iodoacetamide.  The 
second fragment, hCG β42-145 has a mass of 11,505 daltons, much larger than the photolabeled 
fragment in lane 3.  These results suggest that 125I-hLHR17-36(C22Bpa) photoaffinity labeled the N-
terminal portion of hCG β. 
 Digestion of photolabeled hCG α and photolabeled hCG β with Glu C neither confirms 
or refutes these findings.  Two faint bands can be seen in lane 4.  The upper band corresponds to 
photolabeled, deglycosylated, and alkylated hCG α.  The lower band is similar in mass to 125I-
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hLHR17-36(C22Bpa), suggesting that the Glu C generated fragment of hCG α labeled by 125I-
hLHR17-36(C22Bpa) is very small or that there was some problem with the digestion.  A similar 
pattern can be seen in lane 5.  There are two faint bands:  the upper band corresponds to 
photolabeled, deglycosylated, and alkylated hCG β, and the lower band is similar in mass to 125I-
hLHR17-36(C22Bpa).  The bands in lanes 4 and 5 are very faint, illustrating again that Glu C does not 
efficiently digest photolabeled hCG. 
 
D.  Conclusions 
 
 CNBr was able to cleave the hCG/ hLHR17-36(C22Bpa) complex more efficiently than Glu 
C.  In-gel digestions of photolabeled hCG α and photolabeled hCG β with CNBr indicate that the 
N-terminal regions of both hCG α and hCG β were photoaffinity labeled by hLHR17-36(C22Bpa).  
Computer modeling of hCG shows that the N-terminal regions of each subunit are located on the 
convex side of the heterodimer (Figure 3-7).  These results support the idea that the N-terminal 
portion of the receptor wraps around the back of hCG, contacting the convex face of the 
hormone dimer [38].   
 The faintness of the Glu C generated bands in Figure 3-5 makes interpretation of the 
digestion data difficult.  Use of a different chemical cleavage reagent or enzyme in conjunction 
with CNBr could potentially help in further narrowing down the labeling site in hCG α and hCG 
β.  Difficulty lies in finding a cleaving agent that will not digest 125I-hLHR17-36(C22Bpa), resulting 
in loss of the 125I radiolabel.  For example, trypsin could not be used in these experiments 
because it cleaves on the carboxyl side of arginine and lysine residues.  125I-hLHR17-36(C22Bpa) 
contains two Arg residues, Arg21 and Arg31 (Figure 2-3).  While cleavage on the carboxyl side of 
Arg21 would be acceptable, due to formation of a covalent bond by the photoprobe at the Cys22 
position, cleavage on the carboxyl side of Arg31 would effectively remove the radioiodinated Tyr 
residue from the photolabeled hCG/peptide complex.  Chymotrypsin, which preferentially 
cleaves on the carboxyl side of aromatic residues, could be a candidate.   
 Future studies should also include using tandem mass spectrometry to identify the 
actual residues which are covalently modified by hLHR17-36(C22Bpa).  Several, largely unsuccessful 
attempts at this were made.  The fragments of interest, the pieces of hCG α and hCG β 
photolabeled by hLHR17-36(C22Bpa), must be isolated in a quantity great enough to allow for such 
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analysis.  Use of high-performance liquid chromatography (HPLC) during sample preparation 
would facilitate generation of a pure sample.  Edman degradation sequencing could also 
potentially be used to identify the residues which are covalently modified by hLHR17-36(C22Bpa).  
However, this method typically requires more sample than mass spectrometry. 
 Greater understanding of hCG/LH-CG receptor contact sites is the crucial first step in 
the design of hCG-based fertility-enhancing pharmaceuticals and contraceptives.  Innovative 
drugs based on the glycoprotein hormones and their receptors would have a much greater 
specificity than the steroid hormone based contraceptives currently on the market.  These drugs 
are known to impact gene expression in most body cells and can cause serious side effects.  
Glycoprotein hormone and glycoprotein hormone receptor based pharmaceuticals would target 
primarily the gonads, greatly reducing such side effects [27].
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
125I-hCG X X
hCG (0.53µðM) X X X X X X X X X X
125I-Bpa peptide (0.6µΜð)ð G18 G18 A19 A19 L20 L20 R21 R21 C22 C22
Glu C (6%) X X X X X X
Figure 3-1:  Enzymatic digestion of photoaffinity labeled hCG by Endoproteinase 
Glu C.  Radioiodinated Bpa-substituted peptides representing the N-terminal region of 
the hLHR were incubated with hCG and exposed to UV irradiation for 1.5 minutes as 
described in "Materials and Methods".  Samples were digested with 6% Glu C (by weight)
for 18 hours at 25oC as indicated.  Following electrophoresis, the gel was dried and exposed
to a PhosphorImager screen (Molecular Dynamics) overnight.  The imaging screen was 
scanned on a model 860 Storm System Optical Scanner (Molecular Dynamics).  A 
photolabeled, Glu C generated fragment of hCG is indicated with an arrow.
β 
α 
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Figure 3-2:  Enzymatic digestion of photoaffinity labeled deglycosylated hCG by 
Endoproteinase Glu C.  Radioiodinated Bpa-substituted peptides representing the 
N-terminal region of the hLHR were incubated with deglycosylated hCG and exposed 
to UV irradiation for 2 minutes as described in "Materials and Methods".  Samples were
digested with 6% Glu C (by weight) for 18 hours at 25oC as indicated.  Following 
electrophoresis, the gel was processed as described in the legend to Figure 3-1. 
Photolabeled, Glu C generated fragments of deglycosylated hCG are indicated with
arrows.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
125I-dg hCG X X
dg hCG (0.57µΜ) X X X X X X X X X X
125I-Bpa peptide (0.6µΜ)ð G18 G18 A19 A19 L20 L20 R21 R21 C22 C22
Glu C (6%) X X X X X X
β 
α 
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Figure 3-3:  Chemical Cleavage of Photoaffinity Labeled hCG by CNBr.  
A) 125I-hCG, 125I-hCG β, and hCG photolabeled with 125I-hLHR17-36(C22Bpa) were digested 
with CNBr in either 70% formic acid or 70% TFA as indicated.  Gel was processed as 
described in the legend to Figure 3-1.  B)  Contrast was adjusted in image of lanes 8-13.
Photolabeled, CNBr generated fragments are indicated with arrows.
1 2 3 4 5 6 7 8 9 10 11 12 13
125I-hCG X X X
125I-hCG β X X X
125I-C22Bpa/hCG X X X X X X
70% formic acid X X X X
70% TFA X X X X
CNBr X X X X X X X X
α  
β  
A
 
 
β  
α  
B
8 9 10 11 12 13
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1 2 3 4 5 6 7 8 9 10 11 12 13
125I-dg hCG X
125I-hCG X X X X
125I-hCG β X X X X X X X
Neuraminidase X X X X X X
PNGase F X X X X X
O-glycosidase X X X
B
β  
α  
 
Deglycosylated
     hCG α
1 2 3 4 5 6 7 8 9 10 11 12 13
125I-dg hCG X
125I-hCG X X X X
125I-hCG β X X X X X X X
Neuraminidase X X X X X X
PNGase F X X X X X
O-glycosidase X X X
A
β  
α  
 
Deglycosylated
     hCG α
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Figure 3-4:  Enzymatic deglycosylation of 125I-hCG and 125I-hCG β.  A)  Prior to the addition 
of deglycosidases, 125I-hCG and 125I-hCG β were denatured by boiling for 10 minutes in 0.1% 
SDS and 10mM DTT as described in “Materials and Methods”.  Samples were cooled to room 
temperature and neuraminidase, PNGase F, and O-glycosidase were added as indicated.  
Following electrophoresis, gels were processed as described in the legend to Figure 3-1.  B)  
Prior to the addition of deglycosidases, 125I-hCG and 125I-hCG β were denatured by boiling for 
10 minutes in 0.5% SDS and 1% β-mercaptoethanol as described in “Materials and Methods”.  
1% NP-40 was then added to each tube.  After allowing samples to cool completely, 
neuraminidase, PNGase F, and O-glycosidase were added as indicated.   
 
1 2 3 4 5
125I- hCG X
125I- hCG βð X
125I- LHR17-36(C22Bpa) X
CNBr digested αð X
CNBr digested βð X
Glu C digested αð X
Glu C digested βð X
Figure 3-5:  CNBr and Glu C digestion of photolabeled hCG α and photolabeled hCG β.
hCG was photoaffinity labeled with 125I-hLHR17-36(C22Bpa) then deglycosylated with 
neuraminidase, O-glycosidase, and PNGase F.  Bands representing photolabeled, 
deglycosylated hCG α and photolabeled, deglycosylated hCG β were excised from the gel
and digested separately with either CNBr or Glu C as described in "Materials and Methods".
Digestion products were electrophoresed, and the gel was processed as described in the 
legend to Figure 3-1.
β  
α  
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Cleavage of hCG by CNBr 
hCG α  subunit 
APDVQ   DCPEC   TLQEN   PFFSQ   PGAPI   LQCMG   CCFSR   AYPTP   LRSKK   TMLVQ   
KNVTS   ESTCC   VAKSY   NRVTV   MGGFK   VENHT   ACHCS   TCYYH   KS  
hCG β subunit 
SKEPL   RPRCR   PINAT   LAVEK   EGCPV   CITVN   TTICA   GYCPT   MTRVL   QGVLP   
ALPQV   VCNYR   DVRFE   SIRLP   GCPRG   VNPVV   SYAVA   LSCQC   ALCRR   STTDC   
GGPKD   HPLTC   DDPRF   QDSSS   SKAPP   PSLPS   PSRLP   GPSDT   PILPQ 
 
Cleavage of hCG by Endoproteinase Glu C 
hCG α  subunit 
APDVQ   DCPEC   TLQEN   PFFSQ   PGAPI   LQCMG   CCFSR   AYPTP   LRSKK   TMLVQ   
KNVTS   ESTCC   VAKSY   NRVTV   MGGFK   VENHT   ACHCS   TCYYH   KS  
hCG β subunit 
SKEPL   RPRCR   PINAT   LAVEK   EGCPV   CITVN   TTICA   GYCPT   MTRVL   QGVLP   
ALPQV   VCNYR   DVRFE   SIRLP   GCPRG   VNPVV   SYAVA   LSCQC   ALCRR   STTDC   
GGPKD   HPLTC   DDPRF   QDSSS   SKAPP   PSLPS   PSRLP   GPSDT   PILPQ 
 
 
 
Figure 3-6:  CNBr and Endoproteinase Glu C cleavage sites in hCG α and hCG β.  The 
chemical cleavage reagent CNBr cleaves on the carboxyl side of methionine residues.  The 
enzyme Endoproteinase Glu C cleaves on the carboxyl side of glutamate residues.  N-linked 
glycosylation sites are shown in red.  O-linked glycosylation sites are shown in blue. 
 
A	 	 	 	 	 B	 	 	 	 C
Figure 3-7:  hCG fragments photoaffinity labeled by 125I-hLHR17-36(C22Bpa).  Computer
modeling of hCG α (A), hCG β (B), and the hCG heterodimer (C) showing the CNBr
generated fragments photoaffinity labeled by 125I-hLHR17-36(C22Bpa).  The photolabeled 
portion of hCG α is shown in red, and the photolabeled fragment of hCG β is shown in 
blue.
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